Updated guidelines for the management of patients with Lyme disease, babesiosis and human granulocytic anaplasmosis have been released Clinical study 09 February 2013 Pages: 2 - 2
The WHO is urging continued efforts to minimise the impact of major Asia health issues, News item 09 February 2013 Pages: 2 - 2
The US National Comprehensive Cancer Network (NCCN) has announced a number of new updates to its Clinical Practice Guidelines in Oncology Media release 09 February 2013 Pages: 2 - 2
Clinical policy for non-ST segment elevation ACS revised by ACEP Guideline 09 February 2013 Pages: 4 - 4
Drugs major player in varying hospitalisation costs of CF Clinical study 09 February 2013 Pages: 5 - 5
Ethnic women use less contraception than White counterparts in the UK Clinical study 09 February 2013 Pages: 5 - 5
AIDS-related morbidity and mortality is associated with declining household expenditure over time, Clinical study 09 February 2013 Pages: 6 - 6
The medical and economic costs of the effects of second-hand smoke on nonsmokers in the US neared $US6 billion in 2004, Media release 09 February 2013 Pages: 6 - 6
Hydroxyprogesterone delivers well in recurrent preterm labour Clinical study 09 February 2013 Pages: 7 - 7
Lopinavir/ritonavir superior choice for ART-experienced patients Clinical study 09 February 2013 Pages: 8 - 8
Bupropion SR appears to be the most cost-effective smoking cessation therapy compared with nortriptyline and placebo, Clinical study 09 February 2013 Pages: 8 - 8
A universal rotavirus vaccination programme in an infant population in Brazil is cost effective Clinical study 09 February 2013 Pages: 8 - 8
Adding omalizumab to guideline recommended care may be cost effective in patients with severe allergic asthma, Clinical study 09 February 2013 Pages: 9 - 9
Across-the-board price cuts of 5% have been ordered by Italy's pharmaceutical agency for all products paid for by the country's NHS, News item 09 February 2013 Pages: 10 - 10
Growth hormone (GH) treatment for Prader-Willi syndrome will be available fully funded for children in New Zealand, Media release 09 February 2013 Pages: 10 - 10
Amgen has announced that out-of-pocket copayments for cancer patients receiving panitumumab [Vectibix] will be capped Media release 09 February 2013 Pages: 10 - 10
Novartis has reduced the average price of its antimalarial drug Coartem [artemether/lumefantrine] from an average $US1.57 to $US1.00 per treatment Media release 09 February 2013 Pages: 11 - 11